A Comparison of Radiation Techniques in Patients Treated With Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer

Autor: Greg Pond, Anand Swaminath, Peter M. Ellis, Jonathan Peng, Elysia Donovan
Rok vydání: 2020
Předmět:
Adult
Male
Oncology
Cancer Research
medicine.medical_specialty
Lung Neoplasms
Adolescent
medicine.medical_treatment
Population
Kaplan-Meier Estimate
030218 nuclear medicine & medical imaging
Cohort Studies
Young Adult
03 medical and health sciences
0302 clinical medicine
Carcinoma
Non-Small-Cell Lung

Internal medicine
Carcinoma
medicine
Humans
Radiology
Nuclear Medicine and imaging

Stage (cooking)
education
Aged
Neoplasm Staging
Retrospective Studies
Aged
80 and over

education.field_of_study
Radiation
Performance status
Proportional hazards model
business.industry
Radiotherapy Dosage
Retrospective cohort study
Chemoradiotherapy
Middle Aged
medicine.disease
Confidence interval
Radiation therapy
Treatment Outcome
030220 oncology & carcinogenesis
Female
Radiotherapy
Intensity-Modulated

business
Zdroj: International Journal of Radiation Oncology*Biology*Physics. 106:985-992
ISSN: 0360-3016
Popis: Purpose The standard of care in management of patients with good performance status and unresectable stage III non-small cell lung cancer (NSCLC) therapy is concurrent chemoradiation. Newer techniques such as intensity modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) are replacing 3-dimensional conformal radiation (3DCRT) despite low-quality evidence of improved outcomes. We used population-based data to examine survival outcomes by radiation technique. Methods and Materials A population-based retrospective cohort of patients with stage III NSCLC treated with concurrent chemoradiation from 2009 to 2017 in Ontario were identified. The primary outcome was a comparison of overall survival among 3DCRT, IMRT, and VMAT, calculated using the Kaplan-Meier method and compared using log-rank test. Cox regression was used to investigate effect of radiation type on overall survival adjusted for other covariates. Results A total of 3872 patients were treated with 3DCRT (n = 1178), IMRT (n = 1847), or VMAT (n = 847). A decline in 3DCRT and increase in VMAT use were observed over time. Median survival in months was 21.2 (95% confidence interval [CI], 20.0-22.8) for 3DCRT, 23.9 (95% CI, 22.3-25.6) for IMRT, and 24.9 (95% CI, 22.5-27.4) for VMAT, but these differences were not statistically significant (P = .06). Conclusions Our study demonstrates that survival is not compromised in patients receiving IMRT or VMAT (compared with 3DCRT). Thus, given the potential dosimetric advantages associated with these techniques, VMAT and IMRT are recommended for the management of patients with stage III NSCLC.
Databáze: OpenAIRE